Lilly's Orforglipron Outperforms Oral Semaglutide in Head-to-Head Phase 3 Trial
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.